ClinicalTrials.gg
CompletedNCT02839200Updated Apr 13, 2020Results posted

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

A Phase 2 interventional study of ACT-541468 5 mg and ACT-541468 10 mg in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 35 sites in 6 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-04-13.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
5th of 16
360 · median 165
Started
2016
with 1 other
Phase 2
4 of 16
1 open now
Registered
2nd of 16
by date
Lead sponsor
8 of 16
Idorsia Pharmaceuticals Ltd.

Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 2nd registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About daridorexant

daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 389 Sleep Initiation and Maintenance Disorders studies recruiting now, 152 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 108 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.

Read the detailed description

This study consists of the following phases: screening phase; double-blind treatment phase; safety follow-up phase. Safety is monitored throughout the study.

03

Conditions studied

  • Insomnia Disorder

Keywords

  • Insomnia
  • Polysomnography
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Principal inclusion Criteria:

  • Signed prior to any study-mandated procedure.
  • Male or female aged 18-64 years (inclusive).
  • Women of must have negative pregnancy tests and use reliable methods of up to 30 days after EOT.
  • (BMI): 18.5 ≤ BMI (kg/m2) \< 32.0.
  • Insomnia disorder according to criteria.
  • Insufficient sleep quantity as collected subjectively in the sleep diary and validated objectively by polysomnography.
  • Insomnia Severity Index score ≥ 15.

Principal exclusion Criteria:

  • Any current history of sleep disorder other than insomnia, or any lifetime history of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy.
  • Self-reported usual daytime napping ≥ 1 hour per day, and ≥ 3 days per week.
  • Caffeine consumption ≥ 600 mg per day.
  • Shift work within 2 weeks prior to the screening visit, or planned shift work during study.
  • Travel ≥ 3 time zones within 1 week prior to the screening visit, or planned travel > or= 3 time zones during study.
  • Hematology or biochemistry test results deviating from the normal range to a extent as per judgment of the Investigator.
  • and/or ALT > 2 × and/or direct > 1.5 × ULN (except known history of Gilbert's syndrome).
  • Severe renal impairment (known or defined as estimated \< 30 mL/min).
  • History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    ACT-541468 5 mg

    Each subject receives one 5-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks

    Drug: ACT-541468 5 mg · Drug: Placebo 1

  • Experimental
    ACT-541468 10 mg

    Each subject receives one 10-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks

    Drug: ACT-541468 10 mg · Drug: Placebo 1

  • Experimental
    ACT-541468 25 mg

    Each subject receives one 25-mg ACT-541468 capsule (+ one placebo capsule), once daily in the evening) for 4 weeks

    Drug: ACT-541468 25 mg · Drug: Placebo 1

  • Experimental
    ACT-541468 50 mg

    Each subject receives two 25-mg ACT-541468 capsules, once daily in the evening for 4 weeks

    Drug: ACT-541468 25 mg

  • Active comparator
    Zolpidem

    Each subject receives one 10-mg zolpidem capsule (+ one placebo capusle), once daily in the evening for 4 weeks

    Drug: Zolpidem · Drug: Placebo 2

  • Placebo comparator
    Placebo

    Each subject receives two placebo capsules, once daily in the evening for 4 weeks

    Drug: Placebo 1

Interventions

  • Capsule for oral administration containing ACT-541468 at a strength of 5 mg

  • Capsule for oral administration containing ACT-541468 at a strength of 10 mg

  • Capsule for oral administration containing ACT-541468 at a strength of 25 mg

  • Over-encapsulated zolpidem tablet at a strength of 10 mg

  • DrugPlacebo 1

    Placebo capsules matching ACT-541468 capsules

  • DrugPlacebo 2

    Placebo capsules matching over-encapsulated zolpidem

06

What researchers measure

Primary outcomes

  1. Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2

    WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)

    Time frame: Baseline and Days 1&2

Secondary outcomes

  1. Change in Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2

    LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG

    Time frame: Baseline and Days 1&2

  2. Change in Subjective Latency to Sleep Onset (sLSO) From Baseline to Week 4

    sLSO is the self-reported time to fall asleep, as reported in the sleep diary

    Time frame: Baseline and Week 4

  3. Change in Subjective Wake After Sleep Onset (sWASO) From Baseline to Week 4

    sWASO is the self-reported time spent awake after sleep onset as reported in the sleep diary.

    Time frame: Baseline and Week 4

07

Results

Posted Apr 2, 2020

Participant flow

Conducted at 38 sites in 6 countries (Germany, Hungary, Israel, Spain, Sweden, and the USA)

Participant flow — Overall Study
MilestoneACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlacebo
Started605960616060
Completed565859615859
Not completed411021
Withdrew: Withdrawal by subject201001
Withdrew: Lost to follow-up200010
Withdrew: Adverse event000010
Withdrew: Randomized in error010000

Outcome measures

PrimaryChange in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2

WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)

Time frame:
Baseline and Days 1&2
Reported as:
Least squares mean · minutes
Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2
minutesACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlacebo
Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2-28.4 ± 4.24-32.3 ± 4.32-37.7 ± 4.25-47.1 ± 4.21-29.9 ± 4.30-21.4 ± 4.24
Statistical analysis
  • ACT-541468 5 mg vs ACT-541468 10 mg vs ACT-541468 25 mg vs ACT-541468 50 mg vs Placebo · Multiple Comparison Procedure-Model · p = <0.001
  • ACT-541468 5 mg vs Placebo · ANCOVA · p = 0.241 · Ls mean difference: -7 · 95% CI -18.7 to 4.7Parameter Dispersion Type and Dispersion Value: Standard error of the LS mean
  • ACT-541468 10 mg vs Placebo · ANCOVA · p = 0.072 · Ls mean difference: -10.8 · 95% CI -22.6 to 1Parameter Dispersion Type and Dispersion Value: Standard error of the LS mean
  • ACT-541468 25 mg vs Placebo · ANCOVA · p = 0.007 · Ls mean difference: -16.2 · 95% CI -27.9 to -4.5Parameter Dispersion Type and Dispersion Value: Standard error of the LS mean
  • ACT-541468 50 mg vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -25.6 · 95% CI -37.3 to -13.9Parameter Dispersion Type and Dispersion Value: Standard error of the LS mean
  • Zolpidem vs Placebo · ANCOVA · p = 0.155 · Ls mean difference: -8.5 · 95% CI -20.4 to 3.3Parameter Dispersion Type and Dispersion Value: Standard error of the LS mean
SecondaryChange in Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2

LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG

Time frame:
Baseline and Days 1&2
Reported as:
Mean · Minutes
Change in Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2
MinutesACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlacebo
Change in Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2-26.88 ± 45.42-29.31 ± 26.79-36.14 ± 34.34-36.41 ± 26.71-45.14 ± 32.82-22.02 ± 46.63
SecondaryChange in Subjective Latency to Sleep Onset (sLSO) From Baseline to Week 4

sLSO is the self-reported time to fall asleep, as reported in the sleep diary

Time frame:
Baseline and Week 4
Reported as:
Mean · Minutes
Change in Subjective Latency to Sleep Onset (sLSO) From Baseline to Week 4
MinutesACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlacebo
Change in Subjective Latency to Sleep Onset (sLSO) From Baseline to Week 4-13.38 ± 27.79-21.07 ± 24.26-15.50 ± 25.51-23.65 ± 24.12-19.98 ± 19.28-16.32 ± 21.16
SecondaryChange in Subjective Wake After Sleep Onset (sWASO) From Baseline to Week 4

sWASO is the self-reported time spent awake after sleep onset as reported in the sleep diary.

Time frame:
Baseline and Week 4
Reported as:
Mean · Minutes
Change in Subjective Wake After Sleep Onset (sWASO) From Baseline to Week 4
MinutesACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlacebo
Change in Subjective Wake After Sleep Onset (sWASO) From Baseline to Week 4-31.32 ± 33.32-24.35 ± 33.4-29.8 ± 39.88-35.45 ± 37.53-29.08 ± 27.28-23.61 ± 32.62

Adverse events

Collected over Data on adverse events were collected from Screening to Safety Follow-up period. Below, data are reported for treatment-emergent adverse events (TEAEs).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ACT-541468 5 mg0/60 (0%)0/60 (0%)21/60 (35%)
ACT-541468 10 mg0/58 (0%)2/58 (3.4%)22/58 (37.9%)
ACT-541468 25 mg0/60 (0%)0/60 (0%)23/60 (38.3%)
ACT-541468 50 mg0/61 (0%)1/61 (1.6%)21/61 (34.4%)
Zolpidem0/60 (0%)0/60 (0%)24/60 (40%)
Placebo0/60 (0%)0/60 (0%)18/60 (30%)
Most frequent serious events
Most frequent serious events
EventACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlacebo
Myocardial infarctionCardiac disorders0/601/580/600/610/600/60
Accident at workInjury, poisoning and procedural complications0/601/580/600/610/600/60
Craniocerebral injuryInjury, poisoning and procedural complications0/601/580/600/610/600/60
AngioedemaSkin and subcutaneous tissue disorders0/600/580/601/610/600/60
Most frequent other events
Showing 10 of 110
Most frequent other events
EventACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlacebo
HeadacheNervous system disorders6/605/585/605/616/601/60
NasopharyngitisInfections and infestations2/602/580/602/615/604/60
Abdominal pain upperGastrointestinal disorders0/601/580/601/614/601/60
NauseaGastrointestinal disorders0/601/582/601/614/600/60
FatigueGeneral disorders1/601/583/600/614/602/60
DizzinessNervous system disorders1/602/580/600/614/601/60
SomnolenceNervous system disorders3/603/584/604/613/603/60
DiarrhoeaGastrointestinal disorders1/600/583/600/611/602/60
Gait disturbanceGeneral disorders0/600/580/600/612/601/60
Alanine aminotransferase increasedInvestigations0/600/582/601/610/600/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)ACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlaceboTotal
Median41 (22 to 64)48 (21 to 63)48 (18 to 64)46 (18 to 63)43 (23 to 61)48 (23 to 64)47 (18 to 64)
Age, Customized
Age, Customized(Participants)ACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlaceboTotal
Adults (18-64 years)605860616060359
Sex: Female, Male
Sex: Female, Male(Participants)ACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlaceboTotal
Female383839393838230
Male222021222222129
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlaceboTotal
Hispanic or Latino93954939
Not Hispanic or Latino515451565651319
Unknown or Not Reported0100001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgZolpidemPlaceboTotal
American Indian or Alaska Native0000000
Asian0000011
Native Hawaiian or Other Pacific Islander0100001
Black or African American58456735
White544956565452321
More than one race0000000
Unknown or Not Reported1000001
08

Study locations

35 sites
  • Investigator Site
    Santa Monica, California 90404, United States
  • Investigator Site
    Upland, California 91786, United States
  • Investigator Site
    Brandon, Florida 33511, United States
  • Investigator Site
    Clearwater, Florida 33765, United States
  • Investigator Site
    Coral Gables, Florida 33134, United States
  • Investigator Site
    DeLand, Florida 32720, United States
  • Investigator Site
    Hollywood, Florida 33024, United States
  • Investigator Site
    Miami, Florida 33143, United States
  • Investigator Site
    Atlanta, Georgia 30342, United States
  • Investigator Site
    Chicago, Illinois 60634, United States
  • Investigator Site
    Indianapolis, Indiana 46250, United States
  • Investigator Site
    Novi, Michigan 48377, United States
  • Investigator Site
    Las Vegas, Nevada 89104, United States
  • Investigator Site
    New York, New York 10019, United States
  • Investigator Site
    Cincinnati, Ohio 45255, United States
  • Investigator Site
    Berlin, 10115, Germany
  • Investigator Site
    Berlin, 10117, Germany
  • Investigator Site
    Berlin, 12203, Germany
  • Investigator Site
    Dresden, 01069, Germany
  • Investigator Site
    Hamburg, 20251, Germany
  • Investigator Site
    Hamburg, 20253, Germany
  • Investigator Site
    Hannover, 30159, Germany
  • Investigator Site
    Schwerin, 19053, Germany
  • Investigator Site
    Schwerin, 19055, Germany
  • Investigator Site
    Budapest, 1134, Hungary
  • Investigator Site
    Szeged, 6725, Hungary
  • Investigator Site
    Törökbálint, 2045, Hungary
  • Investigator Site
    Beer Sheva, 84101, Israel
  • Investigator Site
    Haifa, 31096, Israel
  • Investigator Site
    Barcelona, 08017, Spain
  • Investigator Site
    Barcelona, 08035, Spain
  • Investigator Site
    Madrid, 28036, Spain
  • Investigator Site
    Zaragoza, 50015, Spain
  • Investigator Site
    Göteborg, 413 90, Sweden
  • Investigator Site
    Örebro, 701 85, Sweden
09

References and documents

Publications

  • Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, Hedner J. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. Ann Neurol. 2020 Mar;87(3):347-356. doi: 10.1002/ana.25680. Epub 2020 Feb 5. Erratum In: Ann Neurol. 2020 Sep;88(3):647-651. doi: 10.1002/ana.25801. PubMed 31953863 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Apr 2017, 6 months.

Results were first posted in Apr 2020, 2 years 11 months after primary completion. A results delay was requested in Apr 2018.

Of 26 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 62 studies reached it within 17 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2016
First posted
Jul 20, 2016
StartActual
Oct 4, 2016
Primary completionActual
Apr 12, 2017
CompletionActual
Jun 20, 2017
Results delay requested
Apr 26, 2018
Results first posted
Apr 2, 2020
Last update
Apr 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02839200
Responsible party
Sponsor
First posted
Jul 20, 2016
Start date
Oct 4, 2016
Primary completion
Apr 12, 2017
Completion
Jun 20, 2017
Results posted
Apr 2, 2020
Last update
Apr 13, 2020

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion